Genor Biopharma Holdings Limited (6998.HK)
HKD 1.66
(-5.68%)
HKD 1.66
(-5.68%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.15 Billion CNY | 25.75% |
| 2022 | -1.56 Billion CNY | 27.21% |
| 2021 | -2.14 Billion CNY | 26.06% |
| 2020 | -2.89 Billion CNY | -1268.87% |
| 2019 | -211.75 Million CNY | -163.35% |
| 2018 | -80.4 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.02 Billion CNY | 11.37% |
| 2024 Q2 | -1.02 Billion CNY | 0.31% |
| 2023 Q1 | -1.33 Billion CNY | 14.22% |
| 2023 FY | -1.15 Billion CNY | 25.75% |
| 2023 Q4 | -1.15 Billion CNY | 0.28% |
| 2023 Q3 | -1.16 Billion CNY | 12.56% |
| 2023 Q2 | -1.32 Billion CNY | 0.74% |
| 2022 Q2 | -1.8 Billion CNY | 0.81% |
| 2022 Q1 | -1.81 Billion CNY | 15.17% |
| 2022 Q4 | -1.56 Billion CNY | 0.43% |
| 2022 FY | -1.56 Billion CNY | 27.21% |
| 2022 Q3 | -1.56 Billion CNY | 13.11% |
| 2021 FY | -2.14 Billion CNY | 26.06% |
| 2021 Q1 | -2.56 Billion CNY | 12.08% |
| 2021 Q4 | -2.14 Billion CNY | 0.35% |
| 2021 Q3 | -2.15 Billion CNY | 15.55% |
| 2021 Q2 | -2.54 Billion CNY | 0.58% |
| 2020 FY | -2.89 Billion CNY | -1268.87% |
| 2020 Q1 | -156.6 Million CNY | 0.0% |
| 2020 Q2 | 196.83 Million CNY | 225.69% |
| 2020 Q4 | -2.91 Billion CNY | 0.0% |
| 2020 Q3 | -2.91 Billion CNY | -1580.28% |
| 2019 Q1 | 125.15 Million CNY | 0.0% |
| 2019 FY | -211.75 Million CNY | -163.35% |
| 2018 FY | -80.4 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -1416.749% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 121.993% |